Hydrogen-rich saline inhibits tobacco smoke-induced chronic obstructive pulmonary disease by alleviating airway inflammation and mucus hypersecretion in rats.
Zibing Liu, Wenye Geng, Chuanwei Jiang, Shujun Zhao, Yong Liu, Ying Zhang, Shucun Qin, Chenxu Li, Xinfang Zhang, Yanhong Si · Experimental biology and medicine (Maywood, N.J.) · 2017
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
The authors concluded that administration of hydrogen-rich water improves lung function and alleviates morphological impairments of lung through alleviating inflammation, reducing oxidative stress and lessening mucus hypersecretion in TS-induced COPD rats. These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
What the Findings Mean
H2HUBB reviewed how hydrogen-rich water affected the outcomes measured in Sprague-Dawley rats. The authors concluded that administration of hydrogen-rich water improves lung function and alleviates morphological impairments of lung through alleviating inflammation, reducing oxidative stress and lessening mucus hypersecretion in TS-induced COPD rats.
What the Researchers Studied
The researchers studied Sprague-Dawley rats. The study used a preclinical animal experiment.
What Effects Did Molecular Hydrogen Have?
Source-reported hydrogen concentration: 0.6 mM H₂ (≈1.21 mg/L); Source-reported hydrogen exposure: 0.6 mM H₂ (≈1.21 mg/L); reported treatment duration: 12 weeks. The authors concluded that administration of hydrogen-rich water improves lung function and alleviates morphological impairments of lung through alleviating inflammation, reducing oxidative stress and lessening mucus hypersecretion in TS-induced COPD rats. The purpose of this study is to evaluate the protective effect of hydrogen-rich water, a novel antioxidant, on chronic obstructive pulmonary disease and explore the underlying mechanism.
Why These Findings Matter
These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
How Strong Is This Evidence?
This is preclinical animal evidence from a preclinical animal experiment. It is most informative for the disease model, mechanisms, biomarkers, and outcomes directly measured in the study.
Technical Study Details
H2HUBB classifies this publication as animal study with preclinical animal evidence. The research population or model was Sprague-Dawley rats. The study used a preclinical animal experiment. The hydrogen delivery method was hydrogen-rich water. The source-reported hydrogen concentration was 0.6 mM H₂ (≈1.21 mg/L). The source-reported hydrogen exposure was 0.6 mM H₂ (≈1.21 mg/L). The reported treatment duration was 12 weeks.
Limitations and Safety
Reported limitations: The global initiative for chronic obstructive lung disease (GOLD) defines COPD as ‘‘a disease state characterized by airflow limitation that is not fully reversible. The airflow limitation is usually associated with an abnormal inflamma- tory response of the lungs to noxious particles or gases.’’ 1 The airway inflammation of COPD patients involves the influx of macrophages, neutrophils and T lymphocytes, and the increase of inflammatory cytokines. bronchoconstriction and airflow limitation are aggravated.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base. The original scholarly source is available at https://www.ebm-journal.org/journals/experimental-biology-and-medicine/articles/10.1177/1535370217725249/pdf.